GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neuland Laboratories Ltd (NSE:NEULANDLAB) » Definitions » Capex-to-Operating-Income

Neuland Laboratories (NSE:NEULANDLAB) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Neuland Laboratories Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Neuland Laboratories's Capital Expenditure for the three months ended in Mar. 2024 was ₹0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was ₹904.54 Mil.

Hence, Neuland Laboratories's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 0.00.


Neuland Laboratories Capex-to-Operating-Income Historical Data

The historical data trend for Neuland Laboratories's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuland Laboratories Capex-to-Operating-Income Chart

Neuland Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.68 0.96 1.02 0.30 0.36

Neuland Laboratories Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Neuland Laboratories's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuland Laboratories's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Neuland Laboratories's Capex-to-Operating-Income falls into.



Neuland Laboratories Capex-to-Operating-Income Calculation

Neuland Laboratories's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1436.698) / 4028.896
=0.36

Neuland Laboratories's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / 904.54
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuland Laboratories  (NSE:NEULANDLAB) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Neuland Laboratories Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Neuland Laboratories's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuland Laboratories (NSE:NEULANDLAB) Business Description

Traded in Other Exchanges
Address
Road No. 82, Jubilee Hills, Plot No. 573A-III, Phoenix IVY Building, 11th Floor (5th Office Level), Hyderabad, TG, IND, 500033
Neuland Laboratories Ltd is a manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry's chemistry needs in Hyderabad. Geographically, it derives a majority of revenue from North America and also has a presence in India, Europe, and Rest of the world.

Neuland Laboratories (NSE:NEULANDLAB) Headlines

No Headlines